Methods of delivering an agent to the eye

Patent metadata

Field	Value
Publication number	US-11963905-B2
Application number	US-202117140505-A
Country	US
Kind code	B2
Filing date	Jan 4, 2021
Priority date	May 7, 2015
Publication date	Apr 23, 2024
Grant date	Apr 23, 2024

Abstract

Methods of delivering agents to structures within the eye are provided.

First claim

What is claimed is:

1. A method of delivering an agent to the retina, the method comprising:
removing at least a portion of the vitreous fluid from the eye, and introducing a fluid detection agent into the eye prior to or during the step of removing at least a portion of the vitreous fluid from the eye;
removing at least a portion of the inner limiting membrane (ILM) to expose a section of the retina;
introducing a non-diluting, fluid replacement material into the eye;
dripping a composition comprising an agent onto the exposed section of the retina; and
maintaining the position of the agent on the exposed retina for a time sufficient to allow the agent to enter cells in the retina;
thereby delivering the agent to the retina.

2. The method of claim 1 , wherein the fluid detection agent is triamcinolone.

3. The method of claim 1 , wherein the portion of the ILM is surgically or enzymatically removed.

4. The method of claim 1 , wherein the portion of the ILM that is removed is from about 0.62 mm 2 to about 62 mm 2 .

5. The method of claim 1 , wherein the ILM is visualized with an ILM-visualization material.

6. The method of claim 5 , wherein the ILM-visualization material is indocyanine green (ICG).

7. The method of claim 1 , wherein the composition comprises from about 50% to about 95% of the agent.

8. The method of claim 1 , wherein the composition further comprises a viscoelastic composition.

9. The method of claim 1 , wherein the agent is selected from the group consisting of a viral delivery vector, a non-viral delivery vector, an antibody, a cell, a small molecule, a nanoparticle, or combinations thereof.

10. The method of claim 9 , wherein the viral delivery vector is selected from the group consisting of adeno-associated virus (AAV), ancestral AAV, adenovirus, lentivirus, retrovirus, herpes simplex virus (HSV), and baculovirus.

11. The method of claim 1 , wherein the non-diluting, fluid replacement material is selected from the group consisting of C3F8, SF6, air, nitrogen, oxygen, perfluoro-n-octane, and silicone oil.

12. The method of claim 1 , wherein the maintaining step comprises maintaining the position of the agent on the exposed retina for at least about 30 minutes.

13. The method of claim 1 , wherein the maintaining step comprises maintaining a subject in a supine or prone position.

14. A method of delivering an agent to a structure in the eye, the method comprising:
removing at least a portion of an eye fluid that contacts or covers a structure in the eye to expose a section of the structure, and introducing a fluid detection agent into the eye prior to or during the step of removing at least a portion of the eye fluid from the eye;
introducing a non-diluting, fluid replacement material into the eye;
dripping a composition comprising an agent onto the exposed section of the structure; and
maintaining the position of the agent on the structure for a time sufficient to allow the agent to enter cells in the structure;
thereby delivering the agent to the structure in the eye.

15. The method of claim 14 , wherein the eye fluid comprises aqueous humour or vitreous fluid.

16. The method of claim 14 , wherein the agent is selected from the group consisting of a viral delivery vector, a non-viral delivery vector, an antibody, a cell, a small molecule, a nanoparticle, or combinations thereof.

17. The method of claim 16 , wherein the viral delivery vector is selected from the group consisting of adeno-associated virus (AAV), ancestral AAV, adenovirus, lentivirus, retrovirus, herpes simplex virus (HSV), and baculovirus.

18. The method of claim 14 , wherein the non-diluting, fluid replacement material is selected from the group consisting of C3F8, SF6, air, nitrogen, oxygen, perfluoro-n-octane, and silicone oil.

Assignees

• Massachusetts Eye & Ear Infirmary

Inventors

• Comander Jason
• Eliott Dean
• Kim Leo
• Vandenberghe Luk H

Classifications

• A61F9/0008 Primary

  Introducing ophthalmic products into the ocular cavity or retaining products therein (putting in contact lenses A61F9/0061; introducing or retaining media in cavities of the body in general A61M31/00) · CPC title

• A61F9/00736

  Instruments for removal of intra-ocular material or intra-ocular injection, e.g. cataract instruments (A61F9/008 takes precedence) · CPC title

• A61F9/00727

  Apparatus for retinal reattachment · CPC title

• A61K31/573

  substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone · CPC title

• A61K49/0034

  Indocyanine green, i.e. ICG, cardiogreen · CPC title